Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism

Area of Science:

• Endocrinology
• Bone Biology
• Metabolic Diseases

Background:

• Hypoparathyroidism (HypoPT) and primary hyperparathyroidism (PHPT) are distinct endocrine disorders impacting bone metabolism.
• Chronic PTH deficiency in HypoPT leads to reduced bone remodeling, increased bone density, and altered microarchitecture.
• Excessive PTH in PHPT causes heightened bone remodeling, favoring resorption and potentially leading to fractures and osteitis fibrosa cystica.

Purpose of the Study:

• To review skeletal involvement in both HypoPT and PHPT.
• To analyze the effects of parathyroid hormone (PTH) on bone in HypoPT.
• To evaluate treatment outcomes for skeletal abnormalities in PHPT.

Main Methods:

• Assessment of bone remodeling, bone mineral density (BMD) via DXA, trabecular bone score, and quantitative computed tomography (QCT).
• Review of data on bone strength and fracture risk in HypoPT and PHPT.
• Evaluation of PTH replacement therapy in HypoPT and parathyroidectomy outcomes in PHPT.

Main Results:

• HypoPT is associated with reduced bone remodeling and increased bone density, with unclear fracture risk.
• PTH treatment in HypoPT may correct some skeletal abnormalities.
• PHPT leads to increased bone resorption, reduced BMD, impaired microarchitecture, and increased fracture risk, which can be improved by parathyroidectomy or medical treatments like bisphosphonates and denosumab.

Conclusions:

• Both HypoPT and PHPT significantly affect skeletal health through distinct mechanisms.
• PTH replacement therapy shows promise for correcting skeletal abnormalities in HypoPT.
• Effective management strategies, including surgery and medical treatments, can mitigate skeletal damage in PHPT.